Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Launched by GRIFOLS THERAPEUTICS LLC · Oct 9, 2018

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for people with acute-on-chronic liver failure (ACLF), a serious condition where the liver is not functioning well due to ongoing damage. The study will compare standard medical treatment with an additional therapy called plasma exchange using a solution called human serum albumin. This trial aims to see if adding this treatment can help improve survival rates for patients who are at high risk of dying from this condition. The study will include about 40 medical centers across the U.S., Canada, and Europe.

To participate, individuals must be between 18 and 79 years old and have a specific type of ACLF. Participants will be randomly assigned to receive either the new treatment plus standard care or just standard care alone. The treatment phase will last between 7 to 17 days, depending on how the patient's condition evolves, followed by a follow-up period of 90 days. Before joining, participants should be aware that certain health issues or medications may make them ineligible, so it’s important to discuss their medical history with the study team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female cirrhotic subjects between 18 and 79 years of age.
• • Subjects with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization (must be ACLF-1b, -2, or -3a within the Screening Period \[a maximum of 10 days\]).
• • Willing and able to provide written informed consent or have an authorized representative able to provide written informed consent on behalf of the subject in accordance with local law and institutional policy.
• • In case of HE, informed consent will be provided by a relative or a legally authorized representative if the subject is considered incompetent to consent.
• Exclusion Criteria:
• • Subjects without ACLF.
• • Subjects with ACLF-1a or ACLF-3b (See Table 2-1 for ACLF grades) after the Screening Period.
• • Subjects fulfilling inclusion criteria that improve to no ACLF or to ACLF-1a or worsen to ACLF-3b during the Screening Period (between initial evaluation and time of randomization).
• • Subjects with ACLF for more than 10 days prior to randomization.
• • Subjects with acute or subacute liver failure without underlying cirrhosis.
• • Subjects with septic shock requiring use of norepinephrine (\> 0.3 mcg/kg/min) or need for a second vasopressor (including terlipressin).
• • Subjects with active bacterial or fungal infection: who have received less than 24h of appropriate antibiotic treatment.
• • Subjects with severe respiratory failure with PaO2/FiO2 ≤200.
• • Subjects with active or recent bleeding (unless controlled for \>48 hours).
• • Subjects with severe thrombocytopenia (≤20×109/L) (based on local laboratory assessment).
• • Subjects with chronic renal failure and currently receiving hemodialysis.
• • Evidence of current locally advanced or metastatic malignancy. Subjects with hepatocellular carcinoma within the Milan criteria (1 nodule ≤5 cm or 3 nodules ≤3 cm \[Appendix 5\]), non-melanocytic skin cancer, and controlled breast or prostate cancer, can be included).
• • Subjects with severe chronic heart failure (New York Heart Association \[NYHA\] class III or IV).
• • Subjects with severe pulmonary disease (Global Obstructive Lung Disease \[GOLD\] stage III or IV).
• • Subjects with severe myopathy as defined clinically.
• • Subjects with a known infection with human immunodeficiency virus (HIV) or have clinical signs and symptoms consistent with current HIV infection.
• • Females who are pregnant, breastfeeding, or if of childbearing potential, unwilling to practice a highly effective method of contraception.
• • Subjects with previous liver transplantation.
• • Subjects receiving anti-platelet or anti-coagulant therapy (LMWH for DVT prophylaxis is allowed).
• • Participation in another clinical study within at least 30 days prior to screening.
• • Subjects with active drug addiction (exceptions: active alcoholism or marijuana).
• • Subjects with a do-not-resuscitate order.
• • In the opinion of the investigator, the subject may have compliance problems with the protocol and the procedures of the protocol.
• • Subjects with current infection of COVID19, those who are less than 14 days post recovery or those who have clinical signs and symptoms consistent with COVID19 infection.